Original Study| Volume 9, ISSUE 4, P243-247, October 2010

Download started.


Differences in Efficacy and Safety Between Capecitabine and Infusional 5-Fluorouracil When Combined With Irinotecan for the Treatment of Metastatic Colorectal Cancer



      Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC). Capecitabine and irinotecan combinations (XELIRI) have been developed for the treatment of this disease but randomized comparisons with standard infusional 5-FU and irinotecan (FOLFIRI) showed conflicting results.

      Patients and Methods

      We searched the literature for randomized controlled trials comparing XELIRI to FOLFIRI for the treatment of metastatic colorectal cancer. Odds ratios with 95% confidence intervals were used to analyze dichotomous variables. Hazard ratios for progression and death were combined with an inverse variance method based on logarithmic conversion. The fixed-effect model and Mantel-Haenszel method were used. Heterogeneity was investigated with the Q-test and I
      • Meta Analysis Group in Cancer
      Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
      . Sensitivity analyses were performed.


      Only 3 studies were identified, involving a total of 450 patients. XELIRI was associated with significantly shorter progression-free survival (PFS) and increased grade 3/4 gastrointestinal toxicities such as nausea, vomiting, and diarrhea. Severe neutropenia, however, was significantly more frequent with FOLFIRI. No differences in responses and febrile neutropenia events were observed.


      Our analysis suggest that the 2 regimens are not equivalent. XELIRI remains an option for the first-line treatment of metastatic CRC but FOLFIRI should be preferred as it confers more benefits in terms of PFS and induces fewer GI toxicities.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J
        • Authier P
        • Boniol M
        • et al.
        Estimates of the cancer incidence and mortality in Europe in 2006.
        Ann Oncol. 2007; 18: 581-592
        • Meta Analysis Group in Cancer
        Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
        J Clin Oncol. 1998; 16: 301-308
        • Köhne CH
        • van Cutsem E
        • Wils J
        • et al.
        Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
        J Clin Oncol. 2005; 23: 4856-4865
        • Saltz LB
        • Cox JV
        • Blanke C
        • et al.
        Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group.
        N Engl J Med. 2000; 343: 905-914
        • Douillard JY
        • Cunningham D
        • Roth AD
        • et al.
        Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial.
        Lancet. 2000; 355: 1041-1047
        • Grothey A
        • Sargent D
        • Goldberg RM
        • et al.
        Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
        J Clin Oncol. 2004; 22: 1209-1214
        • Comella P
        • Casaretti R
        • Sandomenico C
        • et al.
        Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
        Drugs. 2008; 68: 949-961
        • Twelves C
        • Wong A
        • Nowacki MP
        • et al.
        Capecitabine as adjuvant treatment for stage III colon cancer.
        N Engl J Med. 2005; 352: 2696-2704
        • Cassidy J
        • Twelves C
        • Van Cutsem E
        • et al.
        First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
        Ann Oncol. 2002; 13: 566-575
        • Ward S
        • Kaltenthaler E
        • Cowan J
        • et al.
        Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
        Health Technol Assess. 2003; 7: 1-93
        • Fuchs CS
        • Marshall J
        • Mitchell E
        • et al.
        Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study.
        J Clin Oncol. 2007; 25: 4779-4786
        • Köhne CH
        • De Greve J
        • Hartmann JT
        • et al.
        Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
        Ann Oncol. 2008; 19: 920-926
        • Skof E
        • Rebersek M
        • Hlebanja Z
        • et al.
        Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
        BMC Cancer. 2009; 9: 120
        • Rea DW
        • Nortier JW
        • Ten Bokkel Huinink WW
        • et al.
        A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
        Ann Oncol. 2005; 16: 1123-1132
        • Bajetta E
        • Di Bartolomeo M
        • Mariani L
        • et al.
        Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
        Cancer. 2004; 100: 279-287
        • Delord JP
        • Pierga JY
        • Dieras V
        • et al.
        A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
        Br J Cancer. 2005; 92: 820-826
        • Kim TW
        • Kang WK
        • Chang HM
        • et al.
        Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
        Acta Oncol. 2005; 44: 230-235
        • Patt YZ
        • Lee FC
        • Liebmann JE
        • et al.
        Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
        Am J Clin Oncol. 2007; 30: 350-357
        • Folprecht G
        • Grothey A
        • Alberts S
        • et al.
        Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumor response and resection rates.
        Ann Oncol. 2005; 16: 1311-1319
        • Simmonds PC
        • Primrose JN
        • Colquitt JL
        • et al.
        Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies.
        Br J Cancer. 2006; 94: 982-999
        • Wei AC
        • Greig PD
        • Grant D
        • et al.
        Survival after hepatic resection for colorectal cancer metastases: a 10-year experience.
        Ann Surg Oncol. 2006; 13: 668-676
        • Haller DG
        • Cassidy J
        • Clarke S
        • et al.
        Tolerability of fluoropyrimidines appears to differ by region.
        J Clin Oncol. 2006; 24 (abstract 3514).: 149s
        • Garcia-Alfonso P
        • Muñoz-Martin A
        • Mendez-Ureña M
        • et al.
        Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
        Br J Cancer. 2009; 101: 1039-1043
        • Saltz LB
        • Clarke S
        • Díaz-Rubio E
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Moehler M
        • Sprinzl MF
        • Abdelfattah M
        • et al.
        Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.
        World J Gastroenterol. 2009; 15: 449-456
        • Ardavanis A
        • Kountourakis P
        • Mantzaris I
        • et al.
        Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.
        Anticancer Res. 2008; 28: 3087-3092